NEW YORK, March 11 (Reuters) - Cancer therapy company AVEO Pharmaceuticals Inc priced shares in its initial public offering at the bottom of a reduced range on Thursday, according to an underwriter.
The Cambridge, Massachusetts-based company sold 9 million shares for $9 each, raising about $81 million. The company, cut the expected price range to $9 to $10 a share from $13 to $15 earlier on Thursday. It also said it planned to sell 'less than 8 million' shares.
It had earlier filed to sell 7 million shares.
(Reporting by Clare Baldwin, editing by Leslie Gevirtz) Keywords: AVEO/IPO (clare.baldwin@thomsonreuters.com; Reuters Messaging: clare.baldwin.reuters.com@reuters.net; +1 646 223 6189) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
The Cambridge, Massachusetts-based company sold 9 million shares for $9 each, raising about $81 million. The company, cut the expected price range to $9 to $10 a share from $13 to $15 earlier on Thursday. It also said it planned to sell 'less than 8 million' shares.
It had earlier filed to sell 7 million shares.
(Reporting by Clare Baldwin, editing by Leslie Gevirtz) Keywords: AVEO/IPO (clare.baldwin@thomsonreuters.com; Reuters Messaging: clare.baldwin.reuters.com@reuters.net; +1 646 223 6189) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
